Mona Prasad1, George R Saade, Grecio Sandoval, Brenna L Hughes, Uma M Reddy, Lisa Mele, Ashley Salazar, Michael W Varner, Cynthia Gyamfi-Bannerman, John M Thorp, Alan T N Tita, Geeta K Swamy, Edward K Chien, Brian M Casey, Alan M Peaceman, Yasser Y El-Sayed, Jay D Iams, Ronald S Gibbs, Baha Sibai, Nicholas Wiese, Saleem Kamili, George A Macones. 1. Departments of Obstetrics and Gynecology, The Ohio State University, Columbus, Ohio, University of Texas Medical Branch at Galveston, Galveston, Texas, Brown University, Providence, Rhode Island, University of Utah Health Sciences Center, Salt Lake City, Utah, Columbia University, New York, New York, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, University of Alabama at Birmingham, Birmingham, Alabama, Duke University, Durham, North Carolina, MetroHealth Medical Center-Case Western Reserve University, Cleveland, Ohio, University of Texas Southwestern Medical Center, Dallas, Texas, Northwestern University, Chicago, Illinois, Stanford University, Stanford, California, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, Colorado, University of Texas Health Science Center at Houston-Children's Memorial Hermann Hospital, Houston, Texas, and Washington University in St. Louis, St. Louis, Missouri; the Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia; the George Washington University Biostatistics Center, Washington, DC; and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland.
Abstract
OBJECTIVE: To describe the prevalence of hepatitis C virus (HCV) antibody, evaluate current risk factors associated with HCV antibody positivity, and identify novel composite risk factors for identification of groups most likely to demonstrate HCV antibody seropositivity in an obstetric population from 2012 to 2015. METHODS: The Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network initiated an observational study of mother-to-child transmission of HCV in 2012 that included offering HCV antibody screening to their entire obstetric population. Women presenting for prenatal care before 23 weeks of gestation without a known multifetal gestation were eligible. For each woman who was HCV antibody-positive, two women at similar gestational age who were HCV antibody-negative were identified and included for comparison. Risk factors were evaluated by patient interview and chart review. Women in the case group were identified to have a signal-to-cutoff value of at least 5 on the Abbott ARCHITECT platform. RNA status was evaluated for women in the case group. RESULTS: Of 106,842 women screened for the HCV antibody, 254 had positive results. The HCV antibody seroprevalence rate was 2.4 cases per 1,000 women (95% CI 2.1-2.7). One hundred thirty-one women in the case group and 251 women in the control group were included in the case-control analysis. Factors associated with HCV antibody positivity included injection drug use (adjusted odds ratio [aOR] 22.9, 95% CI 8.2-64.0), blood transfusion (aOR 3.7, 95% CI 1.3-10.4), having a partner with HCV (aOR 6.3, 95% CI 1.8-22.6), more than three lifetime sexual partners (aOR 5.3, 95% CI 1.4-19.8), and smoking (aOR 2.4, 95% CI 1.2-4.6). A composite of any of these potential risk factors provided the highest sensitivity for detecting HCV antibody (75/82 cases, 91%). CONCLUSION: In this cohort, the seroprevalence of HCV antibody was low, and the current risk factors for HCV screening were not identified. These findings may be useful in defining new strategies for identifying mothers with the HCV antibody and the neonates susceptible to maternal transmission of HCV. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01959321.
OBJECTIVE: To describe the prevalence of hepatitis C virus (HCV) antibody, evaluate current risk factors associated with HCV antibody positivity, and identify novel composite risk factors for identification of groups most likely to demonstrate HCV antibody seropositivity in an obstetric population from 2012 to 2015. METHODS: The Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network initiated an observational study of mother-to-child transmission of HCV in 2012 that included offering HCV antibody screening to their entire obstetric population. Women presenting for prenatal care before 23 weeks of gestation without a known multifetal gestation were eligible. For each woman who was HCV antibody-positive, two women at similar gestational age who were HCV antibody-negative were identified and included for comparison. Risk factors were evaluated by patient interview and chart review. Women in the case group were identified to have a signal-to-cutoff value of at least 5 on the Abbott ARCHITECT platform. RNA status was evaluated for women in the case group. RESULTS: Of 106,842 women screened for the HCV antibody, 254 had positive results. The HCV antibody seroprevalence rate was 2.4 cases per 1,000 women (95% CI 2.1-2.7). One hundred thirty-one women in the case group and 251 women in the control group were included in the case-control analysis. Factors associated with HCV antibody positivity included injection drug use (adjusted odds ratio [aOR] 22.9, 95% CI 8.2-64.0), blood transfusion (aOR 3.7, 95% CI 1.3-10.4), having a partner with HCV (aOR 6.3, 95% CI 1.8-22.6), more than three lifetime sexual partners (aOR 5.3, 95% CI 1.4-19.8), and smoking (aOR 2.4, 95% CI 1.2-4.6). A composite of any of these potential risk factors provided the highest sensitivity for detecting HCV antibody (75/82 cases, 91%). CONCLUSION: In this cohort, the seroprevalence of HCV antibody was low, and the current risk factors for HCV screening were not identified. These findings may be useful in defining new strategies for identifying mothers with the HCV antibody and the neonates susceptible to maternal transmission of HCV. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01959321.
Authors: Megan G Hofmeister; Elizabeth M Rosenthal; Laurie K Barker; Eli S Rosenberg; Meredith A Barranco; Eric W Hall; Brian R Edlin; Jonathan Mermin; John W Ward; A Blythe Ryerson Journal: Hepatology Date: 2018-11-06 Impact factor: 17.425
Authors: Ravi Jhaveri; Tina Broder; Debika Bhattacharya; Marion G Peters; Arthur Y Kim; Maureen M Jonas Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079
Authors: Gregory L Armstrong; Annemarie Wasley; Edgar P Simard; Geraldine M McQuillan; Wendi L Kuhnert; Miriam J Alter Journal: Ann Intern Med Date: 2006-05-16 Impact factor: 25.391
Authors: Eric E Mast; Lu-Yu Hwang; Dexter S Y Seto; Frederick S Nolte; Omana V Nainan; Heather Wurtzel; Miriam J Alter Journal: J Infect Dis Date: 2005-10-28 Impact factor: 5.226
Authors: H Tajiri; Y Miyoshi; S Funada; Y Etani; J Abe; T Onodera; M Goto; M Funato; S Ida; C Noda; M Nakayama; S Okada Journal: Pediatr Infect Dis J Date: 2001-01 Impact factor: 2.129
Authors: Jodie Dionne-Odom; Gabriella D Cozzi; Ricardo A Franco; Basile Njei; Alan T N Tita Journal: Am J Obstet Gynecol Date: 2021-09-10 Impact factor: 8.661
Authors: Tatyana Kushner; Claire Park; Dana Masand; Brian Wagner; Marie Grace; Emma Rosenbluth; Clara Rodriquez-Rivas; Hernis de la Cruz; Jessica Overbey; Rhoda Sperling Journal: Open Forum Infect Dis Date: 2020-10-23 Impact factor: 3.835